A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.

RM, Fleischmann; H, Bliddal; FJ, Blanco; TJ, Schnitzer; C, Peterfy; S, Chen; L, Wang; S, Feng; PG, Conaghan; F, Berenbaum; JP, Pelletier; J, Martel-Pelletier; O, Vaeterlein; GS, Kaeley; W, Liu; MP, Kosloski; G, Levy; L, Zhang; JK, Medema; MC, Levesque

doi:10.1002/art.40840

Public

A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.

Shared by NobleBlocks on Jun 7, 2019 • 12:00 AM UTC

Authors:

Fleischmann RM

Bliddal H

Blanco FJ

Abstract

Objective To assess the efficacy and safety of the anti-interleukin-1α/β (anti-IL-1α/β) dual variable domain immunoglobulin lutikizumab (ABT-981) in patients with knee osteoarthritis (OA) and evidence of synovitis.Methods Patients (n = 350; 347 analyzed) with Kellgren/Lawrence grade 2-3 knee OA and ...

Discussions